


Clinical Development of Tiotropium HandiHaler® in COPD




↑ improved; ↓ reduced; ≈ comparable.

AE, adverse event; COPD, chronic obstructive pulmonary disease; HRQoL, health-related quality of life; ICS, inhaled corticosteroid; LABA, long-acting β₂-agonist; LAMA, long-acting muscarinic antagonist; PRO, patient-reported outcome; QD, once daily; RCT, randomized controlled trial; SABA, short-acting β₂-agonist; SAMA, short-acting muscarinic antagonist.

1. Littner MR, et al. *Am J Respir Crit Care Med*. 2000;161:1136-1142; 2. Casaburi R, et al. *Chest*. 2000;118:1294-1302; 3. Donohue JF, et al. *Chest*. 2002;122:47-55; 4. Brusasco V, et al. *Thorax*. 2003;58:399-404; 5. Vincken W, et al. *Eur Respir J*. 2002;19:209-216; 6. Casaburi R, et al. *Eur Respir J*. 2002;19:217-224; 7. Niewoehner DE, et al. *Ann Intern Med*. 2005;143:317-326; 8. Dusser D, et al. *Eur Respir J*. 2006;27:547-555; 9. Vogelmeier C, et al. *N Engl J Med*. 2011;364:1093-1103; 10. O'Donnell DE, et al. *Eur Respir J*. 2004;23:832-840; 11. Zhou Y, et al. *N Engl J Med*. 2017;377:923-935; 12. Tashkin DP, et al. *N Engl J Med*. 2008;359:1543-1554; 13. Bateman ED, et al. *Pulm Pharmacol Ther*. 2008;21:20-25; 14. Wedzicha JA, et al. *Am J Respir Crit Care Med*. 2008;177:19-26; 15. Niewoehner DE, et al. *Pulm Pharmacol Ther*. 2009;22:587-592; 16. Griffin J, et al. *Prim Care Respir J*. 2008;17:104-110; 17. Vogelmeier C, et al. *Respir Res*. 2010;11:135; 18. Buhl R, et al. *Eur Respir J*. 2011;38:797-803; 19. Donohue JF, et al. *Am J Respir Crit Care Med*. 2010;182:155-162; 20. Decramer ML, et al. *Lancet Respir Med*. 2013;1:524-533; 21. Beier J, et al. *COPD*. 2013;10:511-522; 22. Chapman KR, et al. *BMC Pulm Med*. 2014;14:4

Clinical Development of Tiotropium Respimat^{®23} in COPD

Clinical Development of Tiotropium + Olodaterol Respimat[®] in COPD



↑ improved; ↓ reduced; ≈ comparable.

23. Dalby RN, et al. *Med Devices*. 2011;4:145-155; 24. van Noord JA, et al. *Respir Med*. 2009;103:22-29; 25. Caillaud D, et al. *Int J Chron Obstruct Pulmon Dis*. 2007;2:559-565; 26. Voshaar T, et al. *Respir Med*. 2008;102:32-41; 27. Bateman ED, et al. *Int J Chron Obstruct Pulmon Dis*. 2010;5:197-208; 28. Bateman ED, et al. *Respir Med*. 2010;104:1460-1472; 29. Wise RA, et al. *N Engl J Med*. 2013;369:1491-1501; 30. Anzueto A, et al. *Respir Res*. 2015;16:107; 31. Calverley PM, et al. *Int J Chron Obstruct Pulmon Dis*. 2017;12:3391-3405; 32. Ferguson F, et al. *Adv Ther*. 2015;32:523-526; 33. Buhl R, et al. *Eur Respir J*. 2015;45:969-979; 34. Beeh KM, et al. *Pulm Pharmacol Ther*. 2015;32:53-59; 35. O'Donnell DE, et al. *Eur Respir J*. 2017;49:1601348; 36. Maltais F, et al. *Thorax*. 2016;12:1753485818755091; 37. Singh D, et al. *Respir Res*. 2016;17:73; 38. Singh D, et al. *Respir Med*. 2015;109:1312-1319; 39. Beeh KM, et al. *Int J Chron Obstruct Pulmon Dis*. 2016;11:193-205; 40. Troosters T, et al. *Am J Respir Crit Care Med*. 2018;198:1021-1032; 41. Bourbeau J, et al. *BMJ Open*. 2016;6:e010109; 42. Troosters T, et al. *BMJ Open*. 2016;6:e010106; 43. Calverley PMA, et al. *Lancet Respir Med*. 2018;6:337-344; 44. Maltais F, et al. *Am J Respir Crit Care Med*. 2018;197:A2373.

Disclosure: The authors meet the criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors received no direct compensation related to the development of this infographic. Writing, editorial support, and formatting assistance was provided by Suchita Nath-Sain, PhD, Saurabh Gagangras, PhD, Praveen Kaul, PhD, and Maribeth Bogush, PhD, of Cactus Communications, which was contracted and funded by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). BIPI was given the opportunity to review the infographic for medical and scientific accuracy, as well as intellectual property considerations.